Sayes Christie M, Staats Herman, Hickey Anthony J
Technology for Industry and the Environment, RTI International, 3040 Cornwallis Rd, Durham, NC, 27709, United States of America.
Pharm Res. 2014 Sep;31(9):2256-65. doi: 10.1007/s11095-014-1415-2. Epub 2014 Jun 12.
The interdependent relationship between pharmacology and toxicology is fundamental to the concepts of efficacy and safety of both drugs and xenobiotics. The traditional concept of establishing efficacious and tolerated doses to define a 'therapeutic window' appears simplistic in the context of an exponentially increasing database on molecular mechanisms and cell biology that inform our understanding of homeostasis. Recent advances in nano medicine illustrate the convergence of efficacy and safety considerations that are central to establishing a clear pathway for regulatory review. The following overview considers biological responses to the administration of nanoparticles and the scale of balanced, within a range that might be considered 'normal', to unbalanced, abnormal responses associated with health and disease.
药理学与毒理学之间的相互依存关系是药物和外源性物质的疗效与安全性概念的基础。在关于分子机制和细胞生物学的数据库呈指数级增长、为我们对体内平衡的理解提供信息的背景下,通过确定有效剂量和耐受剂量来定义“治疗窗”的传统概念显得过于简单。纳米医学的最新进展表明,疗效和安全性考量相互融合,这是建立清晰的监管审查途径的核心。以下概述探讨了纳米颗粒给药后的生物学反应,以及在可能被视为“正常”的范围内从平衡反应到与健康和疾病相关的不平衡、异常反应的规模。